GSK inks up to $750 million deal for cancer-targeting drug

• GSK will pay an upfront fee for full global rights, with Chimagen eligible for additional development and commercial milestone payments
• The trispecific T cell-engager brings T cells and tumor cells together while blocking immune checkpoints to enhance cancer-killing with reduced side effects
• This follows GSK's aggressive oncology expansion including a $10.6 billion acquisition of lung cancer specialist Nuvalent earlier this year and a separate $850 million Chimagen deal in 2024

GSK Acquires Cancer-Targeting Drug in $750M Deal with Chimagen Biosciences

GSK announced on September 15 a licensing agreement worth up to $750 million with China-based Chimagen Biosciences to acquire a trispecific T cell-engager (TCE) for cancer treatment. The deal grants GSK full global rights to the TCE program, with Chimagen eligible for additional development and commercial milestone payments beyond the upfront fee.

Technology and Development

The trispecific TCE is an engineered protein designed to bring T-cells and tumor cells together while blocking immune checkpoints, enhancing the body's cancer-killing ability with reduced off-target effects. GSK plans to develop and commercialize the drug specifically for multiple myeloma, a blood cancer, with Phase 1 trials anticipated to begin in 2027.

Strategic Context

This transaction represents the latest move in CEO Luke Miels' oncology expansion strategy, aimed at bolstering GSK's cancer portfolio ahead of expected patent expirations on its top-selling HIV medications. Earlier in 2024, GSK acquired lung cancer specialist Nuvalent for $10.6 billion—its largest acquisition in over a decade—and secured rights to another experimental drug from Chimagen in a separate deal valued at up to $850 million.

Recent Developments

In October 2025, the FDA approved GSK's blood cancer drug in a combination regimen, marking its return to market nearly three years after withdrawal.

Market Implications

The deal underscores GSK's aggressive push into oncology through strategic acquisitions and licensing agreements, positioning the London-listed pharmaceutical company to offset future revenue losses while expanding its presence in the competitive cancer therapeutics market, particularly in blood cancers.